AC
RPRX icon

ASB Consultores’s Royalty Pharma RPRX Stock Holding History

ASB Consultores’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,119
Closed -$220K – 121
2025
Q2 		$220K Buy
+6,119
New +$203K 0.15% 132
2024
Q2 		– Sell
-11,798
Closed -$358K – 273
2024
Q1 		$358K Buy
+11,798
New +$348K 0.09% 169
2023
Q3 		– Sell
-9,572
Closed -$294K – 185
2023
Q2 		$294K Buy
9,572
+26
+0.3% +$881 0.14% 134
2023
Q1 		$344K Buy
9,546
+1,465
+18% +$54.3K 0.14% 114
2022
Q4 		$319K Buy
8,081
+2,255
+39% +$94.1K 0.13% 119
2022
Q3 		$234K Hold
5,826
– – 0.11% 150
2022
Q2 		$245K Sell
5,826
-331
-5% -$13.6K 0.11% 134
2022
Q1 		$240K Buy
+6,157
New +$242K 0.1% 184

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ASB Consultores's RPRX Position: Q3 2025 in Review

ASB Consultores sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 6,119 shares — an estimated $220K sold.

ASB Consultores first reported a position in RPRX in Q1 2022 and held it in 8 quarters. The position peaked at $358K in Q1 2024. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • ASB Consultores reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • ASB Consultores sold 6,119 Royalty Pharma shares in Q3 2025, an estimated $220K.
  • ASB Consultores first reported a position in Royalty Pharma in Q1 2022 and held it in 8 quarters.
  • ASB Consultores's Royalty Pharma position peaked at $358K in Q1 2024.
  • 488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on ASB Consultores's 13F filing for Q3 2025, filed 4 Nov 2025.